Date:8/6/2009

(4,567) (5,641) Discontinued Operations: Loss from discontinued operations - (5,165) (29) (5,729) Gain on sale of Ibis Biosciences, Inc., net of tax - - 171,773 - ------- ------- ------- ------- Net income (loss) from discontinued operations, net of tax - (5,165) 171,744 (5,729) ------- ------- ------- ------- Net income (loss) (3,753) (4,702) 167,177 (11,370) Net loss attributable to noncontrolling interest in Regulus Therapeutics Inc. 857 965 1,771 1,848 ------- ------- ------- ------- Net income (loss) attributable to Isis Pharmaceuticals, Inc. common stockholders $(2,896) $(3,737) $168,948 $(9,522) ======= ======= ======= ======= Basic net income (loss) per share: Net income (loss) from continuing operations attributable to Isis Pharmaceuticals, Inc. common stockholders $(0.03) $0.02 $(0.03) $(0.04) Net income (loss) from discontinued operations - (0.06) 1.76 (0.06) ------- ------- ------- ------- Basic net income (loss) $(0.03) $(0.04) $1.73 $(0.10) ======= ======= ======= ======= Shares used in computing basic net income (loss) per share 98,116 94,675 97,820 92,737 ======= ======= ======= ======= Diluted net income (loss) per share: Net income (loss) from continuing operations attributable to Isis Pharmace
'/>"/>

SOURCE Isis Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results